LONG MINI-FUTURE - BIOGEN IDEC | Delayed Deutsche Boerse AG 16:03:59 23/05/2024 BST | ||
| 4.34 EUR | -14.23% |
|
| Current month | +19.34% | ||
| 1 month | +116.24% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
BIOGEN INC.
Latest news about BIOGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 4.34 | -14.23% |
| 22/05/24 | 5.06 | +0.60% |
| 21/05/24 | 5.03 | -8.55% |
| 20/05/24 | 5.5 | +3.19% |
| 17/05/24 | 5.33 | +0.19% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 04:03 pm
More quotesStatic data
| Product type | Warrant Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BIOGEN INC. |
| Issuer | 
Vontobel
|
| WKN | VX8LN8 |
| ISIN | DE000VX8LN88 |
| Date issued | 11/03/2022 |
| Strike | 172.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 5.02 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.1 € |
|---|---|
| Lowest since issue | 1.79 € |
| Spread | 0.03 € |
| Spread % | 0.69% |
Company Profile
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
-
Consensus: Biogen Inc.
Sell
Buy
Mean consensus
BUY
Number of Analysts
33
Last Close Price
225.2
USD
Average target price
287.3
USD
Spread / Average Target
+27.57%
- Stock Market
- Certificates
- Certificat
